Baird Downgrades Regeneron Pharma (REGN) to Neutral; EPS Expectations Will Be Hard to Meet
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron Pharma (REGN) PT Trimmed to $511 at Leerink Partners
August 5, 2016 8:03 AM EDTLeerink Partners analyst Geoffrey Porges trims its price target on Regeneron Pharma (NASDAQ: REGN) to $511.00 (from $530.00) but maintains an Outperform rating amid solid Q2 results.
Porges commented, "Regeneron announced solid 2Q16 results, with Eylea beating by 2% in the US and 5% overall; total... More
Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues
August 4, 2016 2:55 PM EDTRoth Capital affirms Regeneron (Nasdaq: REGN) with a Buy rating and $520 price target following Q2 results and updated guidance, as reported... More
